Larimar Therapeutics Inc (LRMR)

[vectorinformatics]

Steinmeyer Law launched a class action lawsuit against Zafgen on behalf of shareholders ZFGN Class Action Lawsuit Homepage

[T695]

Too early

[Wildbilly]

I'm in $5.94

[doglover1]

This one's toast. Glad I bailed shortly after the first death, in the low teens.

Tough luck, guys.

They have a drug that can reduce obesity, although now deemed totally unsafe. Possibly they could dilute it way down and try testing it again as an over the counter appetite depressant (or something.) Maybe something like that could keep the company afloat.

[KurtSTi]

Bull. Shit.

[LordTurkeyBaster]

So insightful. I just cannot contain myself

[Wildbilly]

Zafgen down further after hours as complete clinical hold ordered - Zafgen, Inc. (NASDAQ:ZFGN)

Well, there we have it, I'll really be paying attention now.

Following another death in its Phase 3 trial for lead product candidate beloranib, Zafgen (ZFGN -60.6%) says now that its IND application for the drug has been placed on complete clinical hold.

Shares are down another 2.7% after hours following the news, after today's decline steepened from a premarket drop.

The drug had been placed on a partial clinical hold in October, after the first death related to blood clots in the trial.

The order is to suspend all clinical work under the application.

"We remain committed to advancing beloranib as a potential new therapy for this underserved patient population [with Prader-Willi Symdrome]," said CEO Dr. Thomas Hughes.

Previously: Zafgen reports another blood clot-related death in its late-stage study of beloranib in obese patients with Prader-Willi syndrome; shares off 37% premarket (Dec. 02 2015)

http://seekingalpha.com/news/2962446-zafgen-down-further-after-hours-as-complete-clinical-hold-ordered?uprof=44#email_link

[trendmkr]

Today’s Movers and Shakers in Biotech - article discusses Zafgen

http://marketexclusive.com/movers-and-shakers/1124/

[K_Thomas]

Did you sell out today?

[ClayTrader]

* * $ZFGN Video Chart 12-02-15 * *

Link to Video - click here to watch the technical chart video

[magness]

worst day ever. thank God I have a well diversified portfolio.

[Wildbilly]

I haven't followed as closely as I should,

but they closed that portion of the trial, however there was nothing indicated that patient was anticoagulated at that point.

"After review of its ongoing clinical trials, the Company has elected to proceed with efficacy and safety data analysis and close the randomized portion of its Phase 3 ZAF-311 clinical trial of beloranib in patients with Prader-Willi syndrome (PWS) and its ZAF-203 Phase 2b clinical trial of beloranib in patients with severe obesity complicated by type 2 diabetes. Zafgen believes that a sufficient number of patients have completed randomized treatment in both clinical trials to assess the efficacy of beloranib and help inform next steps for the beloranib program. Following the partial clinical hold announced last week, the Company believes it can best preserve the integrity of the data in each clinical trial by closing the randomized portion of the clinical trials early. The Company, based on consultation with the U.S. Food and Drug Administration (FDA), expects ZAF-311 to remain a pivotal clinical trial. The Company expects to report top-line results from both the ZAF-311 and ZAF-203 clinical trials in the first quarter of 2016."

Zafgen Announces Beloranib Program Update - Yahoo Finance
http://finance.yahoo.com/news/zafgen-announces-beloranib-program-103000257.html

[novicetrader]

was the partial hold that was placed after the 1st patient death removed? Or is Zafgen still under that partial hold? Sorry,haven't followed this company before now

[Wildbilly]

A clinical hold is the biggest concern

PWS is a wicked condition, they need to blackbox the drug and carry on.

[TopPick]

They may scrap the drug now though

[K_Thomas]

The buyers are back in.

[K_Thomas]

I would get in now while you can.
We already saw the price go up over 40% after the last patient death because it was unrelated to beloranib.
This is no different. We already know this new patient's death was unrelated to the drug.

[power_forward]

so the operation was a success but the patient died lol

[Wildbilly]

Thanks for the update.

[balamidas]

the patient had a pulmonary problem which is not related to ZFGN drug targeting obesity

ZFGN is likely to bounce today after players realize that and weak hands are bought down here

[power_forward]

oops, now ANOTHER patient died

[Wildbilly]

Zafgen Says Another Patient Dies in Beloranib Study
FDA had placed beloranib on partial clinical hold in October following another patient’s death
By ANNE STEELE

Updated Dec. 2, 2015 7:59 a.m. ET

Zafgen Inc. said Wednesday that another patient died during a continuing study of a rare genetic disorder, two months after U.S. regulators temporarily halted its clinical trial to investigate circumstances surrounding the previous death.

Shares, which closed Tuesday at $15.93, fell 55% to $7.11 in premarket trading.

The biopharmaceutical company said it learned Tuesday that a patient being treated with beloranib for Prader-Willi syndrome was diagnosed with bilateral pulmonary emboli—blood clots to the lung—and died.

The patient was receiving the drug during the open-label extension portion of the late-stage trial.

Prader-Willi syndrome is a genetic disorder that results in life-threatening obesity because of unrelenting hunger. There is no cure for the disease, which affects one in 12,000 to 15,000 people, according to Prader-Willi Syndrome Association.

In October, Zafgen disclosed that a patient had died during the belanorib study. The U.S. Food and Drug Administration placed beloranib on partial clinical hold because of the thromboembolic events—blood clots that move after forming and block other vessels—in other trials of beloranib and the unknown nature of that death.

On Tuesday, Chief Executive Thomas Hughes said Zafgen is in talks with the FDA while determining next steps for the program.

“Our thoughts are with the patient and their family at this time,” he said. “Patient safety remains our top priority, and we are investigating the circumstances around this event.”

The company reiterated its expectation for “top-line results” of the randomized portion of the clinical trial in the first quarter of 2016.

Zafgen Says Another Patient Dies in Beloranib Study - WSJ
http://www.wsj.com/articles/zafgen-says-another-patient-dies-in-beloranib-study-1449059965

[K_Thomas]

Still cannot believe how undervalued this stock is. The reason why it dipped so low was due to a scare that the trial patient's death was linked to the beloranib, but we found out a month ago that it wasn't related at all!
This stock will recover its 52 wk high.

[K_Thomas]

Time to buy!
First red day in weeks.

[K_Thomas]

Excited for another big week of gains starting tomorrow!

[magness]

Hey shorts, how are you doing over there? Ready to cover? Get ready, before it's too late.

[magness]

I hope the momentum will build while we're going closer to $20!

[magness]

Decent move today, but still it's struggling to break through 15s zone... My sentiment: strong hold.

[stocktrademan]

$ZFGN recent news/filings

bearish 15.31

## source: finance.yahoo.com

Thu, 19 Nov 2015 04:00:00 GMT ~ IMPORTANT INVESTOR ALERT: Marcus & Boxerman Announces an Ongoing Investigation of Zafgen, Inc. and Encourages Investors to Contact the Firm

[Business Wire] - Marcus & Boxerman announces that it is investigating claims of potential misrepresentations by Zafgen, Inc. . The investigation will focus on whether the Company and its officers violated securities laws by issuing misleading information to investors.

read full: http://finance.yahoo.com/news/important-investor-alert-marcus-boxerman-040000010.html
*********************************************************

Wed, 18 Nov 2015 23:24:00 GMT ~ Investor Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 From Investment in Zafgen, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – ZFGN

[GlobeNewswire] - STEVENSON, Md., Nov. 18, 2015-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...

read full: http://finance.yahoo.com/news/investor-alert-brower-piven-encourages-232400689.html
*********************************************************

Wed, 18 Nov 2015 20:27:00 GMT ~ Zafgen, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

[Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Zafgen, Inc.

read full: http://finance.yahoo.com/news/zafgen-inc-shareholder-alert-former-202700361.html
*********************************************************

Wed, 18 Nov 2015 15:32:03 GMT ~ Can the Rally in Zafgen (ZFGN) Shares Continue?


read full: http://finance.yahoo.com/news/rally-zafgen-zfgn-shares-continue-153203001.html
*********************************************************

Tue, 17 Nov 2015 17:11:00 GMT ~ INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zafgen, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of December 21, 2015 – ZFGN

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 17, 2015 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Zafgen, Inc. ...

read full: http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-171100089.html
*********************************************************

$ZFGN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ZFGN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ZFGN/company-info
Ticker: $ZFGN
OTC Market Place: Not Available
CIK code: not found
Company name: Zafgen, Inc.
Incorporated In:

$ZFGN share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ZFGN extra dd links

Company name: Zafgen, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZFGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZFGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZFGN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/news - http://finance.yahoo.com/q/h?s=ZFGN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZFGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZFGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZFGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zafgen%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zafgen%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zafgen%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZFGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZFGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZFGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZFGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZFGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZFGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZFGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZFGN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZFGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZFGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZFGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZFGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZFGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZFGN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZFGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZFGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZFGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZFGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZFGN



$ZFGN DD Notes ~ http://www.ddnotesmaker.com/ZFGN

[magness]

This is above 15. I think we're back on track now!

[magness]

The stock currently has a Zacks Rank #2 (Buy) http://finance.yahoo.com/news/rally-zafgen-zfgn-shares-continue-153203001.html

[K_Thomas]

Not exactly the highest amount of volume I was looking for, but we're looking great at mid-day!

[K_Thomas]

What makes you think that it is temporary?
It seems that this stock is having a hard time breaking, especially with such little volume.
I really thought that after news came out the patient death wasn't related to the medication we would see a continued sharp spike but it's not the case.

[magness]

Weird resistance at $15 today, but it's temporary.

[ospreyeye]

$ZFGN Chart from yesterday – broke resistance yesterday – it is now support – the red horizontal line is now green – notice how low of day the last 2 days hit the previous resistance level – it is turning into support – the opening price on Oct. 16th is the next resistance level to break – 15 is on deck – RSI @ 39.73 has a ton of room to run – RSI is not overbought until 70 – Fast STO bull cross & back in the above 80 overbought/power zone – MACD bull cross last week – when we say say bull cross we are referring to the black line(MACD Line) crossing the purple line(Signal Line) to the upside on this chart –

[ronk]

Huh. Just checked the chart on this.

[ospreyeye]

$ZFGN Chart from yesterday – Bullish move above the middle Bollinger Band @ 11.41 – when the middle BB turns into support a new up trend can begin – light volume today – RSI @ 38.90 has juice/room to run – Fast STO is in the above 80 overbought/power zone – MACD bull cross last week – light volume – keep an eye out for a spike –

[ospreyeye]

$ZFGN Charts – Technical Analysis Video –

[Wildbilly]

Sweet move, dammit!

[Wildbilly]

ZFGN's CC sounded encouraging to me plus the earnings seemed ok considering, although AH action was a little sleepy, loss of 73 cents per share beat wall street expectations of 80 cents.

Only two have dropped out of the trial and 55 remain, the FDA says Z311 will remain a pivotal study and apparently belonarib was not the cause of the patients death.

Zafgen's (ZFGN) CEO Tom Hughes on Q3 2015 Results - Earnings Call Transcript | Seeking Alpha
http://seekingalpha.com/article/3674356-zafgens-zfgn-ceo-tom-hughes-on-q3-2015-results-earnings-call-transcript?part=single

[Wildbilly]

Needs something to bring volume back in

One of the things I like to look at for a scalp or quick swing/bounce is ADX(2) +D1/-D1 cross and RSI (30) cross 20 (which is still good), so it wouldn't be ready for my purposes yet unless there's a catalyst. Yesterday's action could be the start of a handle on that cup tho', eh?

[ospreyeye]

$ZFGN Chart – nice follow through today after 2 closes in a row above EMA 4 – making a strong move above EMA 8 @ 11.02 – that is the key level to close above today – the last close above EMA 8 was back in the 1st week of Oct. – high of day on Oct. 19th is the 2nd level to break – a close above puts the middle Bollinger band @ 14.72 on deck – RSI & Fast STO are above oversold levels – light volume –

[Wildbilly]

I think I got $18 for one

and $27 for the other, I've tried to put those out of my memory.

[doglover1]

A few years back I joined two class actions, one against Allied Artists and I forget the other. Received 2 checks, both for less than $1.00.

Attorneys manage to retain about 90% of settlements in the lawsuits. Congress did try a few years back to make it more equitable for shareholders, but Democrats voted it down. Of course, attorneys, along with other low life groups, are part of the Democratic base, so it was to be expected.

[Wildbilly]

It ended up being more about the NASDAQ

and a tempest in a teapot regarding FB, with any opening at all it's automatic modus operandi of trolling law firms.

I remember joining a couple in the early 2000's and the best I did was a couple of pennies on the dollar with a

Proctor & Gamble class action, total waste of time.

[doglover1]

Oh, I guess there's still a ways to go here then.....

[Wildbilly]

We counted 40 something after Facebook's IPO

before we stopped keeping count.

[doglover1]

Regardless, company will still be forced to spend a lot of money on attorney fees fighting these dozen or so cases.

If judges find merit with the cases, company will be forced to spend a whole lot of money, whether it's fighting it in court or settling out of court.

I don't recall ever seeing another company garner this many class action lawsuits in such a short amount of time as here, except for possibly Exxon and BP.

Seems like roaches coming out of the woodwork here.

[CalderQuacks]

LOL, so many law firms wanting $$. Maybe 1 will actually result in a case which will in turn result in the shareholder getting less than $1 a share.

I highly doubt any of these class action lawsuits will ever materialize.

[Klinsmann]

THX. Maybe better to see a reversal here to at least above 20$, than most may average down and leave this stock with gains. Best solution for all ;)